Link: https://discuss.online/api/v3/image_proxy?url=https%3A%2F%2Fimg.youtube.com%2Fvi%2FtuZBgSTV7Kg%2Fmaxresdefault.jpg

Dr Helena Popovic MBBS is a medical doctor and international speaker who shows people how to boost their brain at any age or stage of life. She graduated from the University of Sydney and has spent over 30 years researching the brain and teaching people how to reach their full potential. She also provides a roadmap for living longer, stronger, healthier and happier.

Dr Helena’s philosophy is that education is more powerful than medication and she believes in growing bolder rather than older. She is the author of three best-selling books 'In Search of My Father', 'Adventure Prevents Dementia' and 'NeuroSlimming - Let Your Brain Change Your Body' and is one of Australia’s most popular conference opening speakers.

https://youtu.be/tuZBgSTV7Kg

:::spoiler summerizer

Nutrition link to dementia — transcript-based summary

Framing and core thesis

• Dementia risk is presented as strongly modifiable, with nutrition positioned as a primary lever alongside other lifestyle factors.
• Brain physiology is emphasized: the brain is <2% of body weight yet uses ~20% of blood supply and ~20% of energy, generating ~20% of body heat.

Reported population-level risk framing

• A 2024 “commission report” is cited as indicating the global burden of dementia could be reduced by ~40%, with the speaker stating nutrition is not explicitly included in that list despite being foundational to multiple listed factors.

Diet pattern risk claims and cohort evidence cited in the talk

• Ultra-processed foods:

  • A cohort study is described as following ~10,000 adults for ~8 years, with higher ultra-processed food intake associated with:
    • ~28% faster global cognitive decline.
    • ~25% faster executive function decline.
  • A rule-of-thumb claim is stated: every 10% increase in ultra-processed food intake is associated with ~15% higher type 2 diabetes risk.

• Type 2 diabetes as a dementia risk amplifier:

  • Midlife type 2 diabetes is described as “doubling” dementia risk later in life.
  • Specific multipliers are stated:
    • ~2.3× increased dementia risk in women with type 2 diabetes.
    • ~1.7× increased dementia risk in men with type 2 diabetes.

Mechanistic narrative emphasized

• Sugar chemistry:
  • Sucrose is described as composed of glucose + fructose.
  • Fructose is described as being handled differently from glucose and, at current consumption patterns, contributing to systemic and brain-related harm.
• Fructose-related brain/metabolic claims:
  • Fructose intake is described as reducing ATP and increasing uric acid in neurons.
  • Downstream effects named: oxidative stress, insulin resistance, leptin resistance.
  • Satiety claim: reducing sugar (especially fructose) is described as reducing hunger over time.

Oral health as a dementia-related pathway

• Poor oral hygiene (not brushing/flossing) is described as associated with higher Alzheimer’s/cognitive decline risk.
• Gum disease bacteria are described as able to travel to the brain (Porphyromonas gingivalis is named in the talk).

Risk factors list explicitly named in the Q&A segment

• Sleep deprivation.
• Stress.
• Alcohol: >~4 standard Australian drinks/week is stated to “start to shrink your brain” and increase dementia risk.
• Smoking.
• Low vitamin D (“sun starvation”).
• Sedentary living / low muscle strength (sarcopenia is referenced).
• Air pollution/smog/smoke.
• Traumatic brain injury (“smashing your head”).
• Sensory loss (hearing is implied by “sensory loss,” with emphasis on reduction).
• Chronic severe midlife depression (untreated).
• Low novelty / low mental stimulation.
• Social isolation and loneliness; loneliness is stated to be as damaging as smoking ~15 cigarettes/day.

Dietary strategy emphasized for symptomatic support in dementia

• Ketogenic diet framing:

  • Presented as the primary dietary intervention offered in clinical practice for dementia patients.
  • Rationale given: ketones as an alternative brain fuel when glucose metabolism is impaired.
  • A 12-week modified ketogenic diet trial is described as reporting improvements in quality of life and daily function.

• MCT oil implementation:

  • MCT is defined as medium-chain triglycerides; liver conversion to ketones is described.
  • Source described: coconuts.
  • Practical dosing guidance is described qualitatively (start slow; add to foods such as eggs/vegetables).
  • Anecdotal report: missing a day of MCT oil is described as being noticed as worse cognitive function by some individuals.

Nutrients and supplements emphasized

• Omega-3 fats:

  • Stated as important throughout life.
  • APOE4-specific claim: APOE4 carriers (after ~50–60 years) are described as absorbing omega-3 less well than non-carriers.
  • Vegetarian/vegan guidance: omega-3 supplementation is recommended.
  • High omega-6 diet (seed oils) is stated to impair conversion of ALA to DHA.

• Choline:

  • Described as essential for brain health and as a precursor for acetylcholine (stated as deficient in Alzheimer’s).
  • Food examples stated to contain choline: soybeans, shiitake, broccoli, almonds.

• Creatine:

  • Described as an emerging intervention with limited studies to date.
  • Clinical practice claim: ~5 g/day prescribed for dementia patients.
  • Food equivalence claim: ~10 g creatine from ~2 tins of sardines/day is stated.
  • Sardines are also positioned as beneficial via omega-3 + creatine.

• B vitamins / homocysteine:

  • Biomarkers emphasized: B12 and homocysteine.
  • High homocysteine is described as an early risk signal and linked to brain shrinkage before symptoms.
  • Intervention described: high-dose B6/B9/B12 to lower homocysteine, referencing a named trial.

Papers / Trials (DOI)

• Ultra-processed food consumption and cognitive decline (JAMA Neurology; 2022/2023): 10.1001/jamaneurol.2022.4397
• Modified ketogenic diet in Alzheimer’s disease; randomized crossover (Alzheimer’s Research & Therapy, 2021): 10.1186/s13195-021-00783-x
• VITACOG: B vitamins lowering homocysteine and brain atrophy in MCI (PLOS ONE, 2010): 10.1371/journal.pone.0012244

:::